BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 14.0//EN
BEGIN:VTIMEZONE
TZID:Central Standard Time
BEGIN:STANDARD
DTSTART:20251102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Central Standard Time
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Central Daylight Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Precise genome editing using CRISPR-Cas9 is a promising avenue 
 for genetic disease research. However\, off-target editing effects can com
 plicate and slow research.  \nIn this webinar\, Dr. Matthew Coelho discuss
 es findings recently published in Nature Communications\, &ldquo\;CRISPR G
 UARD protects off-target sites from Cas9 nuclease activity using short gui
 de RNAs.&rdquo\; \nIn this webinar\, he will:\n\n    Discuss the utility o
 f CRISPR Guide RNA Assisted Reduction of Damage (CRISPR GUARD) as a method
  for protecting off-target sites by co-delivery of short guide RNAs (sgRNA
 s) directed against off-target loci by competition with the on-target guid
 e RNA.\n    Explore design rules and the universality of this CRISPR GUARD
  method through in vitro studies and high-throughput screening\n    Short 
 benefit statement for why one would want to attend the event\; &lt\;50 wor
 ds\; include as many SEO keywords as possible\, without stuffing\n\nFor re
 search use only. Not for use in diagnostic procedures. Unless otherwise ag
 reed to in writing\, IDT does not intend these products to be used in clin
 ical applications and does not warrant their fitness or suitability for an
 y clinical diagnostic use. Purchaser is solely responsible for all decisio
 ns regarding the use of these products and any associated regulatory or le
 gal obligations.
DTEND:20220519T170000Z
DTSTAMP:20260810T224953Z
DTSTART:20220519T160000Z
LOCATION:Virtual
SEQUENCE:0
SUMMARY:Limit off-target editing with CRISPR GUARD
UID:RFCALITEM639219989930186357
X-ALT-DESC;FMTTYPE=text/html:<p>Precise genome editing using CRISPR-Cas9 is
  a promising avenue for genetic disease research. However\, off-target edi
 ting effects can complicate and slow research.  </p>\n<p>In this webinar\,
  Dr. Matthew Coelho discusses findings recently published in Nature Commun
 ications\, &ldquo\;CRISPR GUARD protects off-target sites from Cas9 nuclea
 se activity using short guide RNAs.&rdquo\; </p>\n<p>In this webinar\, he 
 will:</p>\n<ul>\n    <li>Discuss the utility of CRISPR Guide RNA Assisted 
 Reduction of Damage (CRISPR GUARD) as a method for protecting off-target s
 ites by co-delivery of short guide RNAs (sgRNAs) directed against off-targ
 et loci by competition with the on-target guide RNA.</li>\n    <li>Explore
  design rules and the universality of this CRISPR GUARD method through in 
 vitro studies and high-throughput screening</li>\n    Short benefit statem
 ent for why one would want to attend the event\; &lt\;50 words\; include a
 s many SEO keywords as possible\, without stuffing\n</ul>\n<p class="margi
 n-top-lg disclaimer-text">For research use only. Not for use in diagnostic
  procedures. Unless otherwise agreed to in writing\, IDT does not intend t
 hese products to be used in clinical applications and does not warrant the
 ir fitness or suitability for any clinical diagnostic use. Purchaser is so
 lely responsible for all decisions regarding the use of these products and
  any associated regulatory or legal obligations.</p>
END:VEVENT
END:VCALENDAR